About the Authors

Michael Lehrke, Segan C Millington, Nayyar Iqbal, Mitchell A Lazar
Divisions of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

Muredach P Reilly, Daniel J Rader
Cardiology Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

Muredach P Reilly, Daniel J Rader
Center for Experimental Therapeutics and Penn Diabetes Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

Corresponding Author

lazar@mail.med.upenn.edu

Competing Interests

MPR has received research funding or honoraria from GlaxoSmithKline, Merck, Ely Lilly, and KOS Pharmaceuticals. MAL has received a research grant from GlaxoSmithKline and has a United States patent application pending for therapeutic antagonism of human resistin. MAL and the University of Pennsylvania have licensed to Linco the monoclonal antibodies used in the human resistin assay.

Author Contributions

ML, MPR, NI, DJR, and MAL designed the study. ML, MPR, and SCM performed experiments. ML, MPR, NI, and MAL analyzed the data. MPR and NI enrolled patients. ML, MPR, NI, DJR, and MAL contributed to writing the paper. MAL obtained funding for the study and provided the research environment where the studies were conducted.